Antidepressant properties of Proproten and amitriptyline: comparative experimental study

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Depression is a prevalent mood disorder with significant unmet therapeutic needs.
• Current antidepressant treatments, like amitriptyline, can have side effects such as sedation.
• S100 protein plays a role in neuronal function and may be implicated in mood disorders.

Purpose of the Study:

• To investigate the antidepressant properties of Proproten, which consists of antibodies to S100 protein in ultralow doses.
• To compare the efficacy and side effect profile of Proproten with a standard antidepressant, amitriptyline.
• To evaluate the effects of both single and repeated administration of Proproten.

Main Methods:

• Utilized outbred albino rats for behavioral studies.
• Employed the Porsolt's test of behavioral helplessness to assess antidepressant-like activity.
• Used Nomura's test of forced swimming with freely rotating wheels to evaluate motor activity and antidepressant effects.

Main Results:

• Proproten, at a dose of 2.5 ml/kg, exhibited a strong antidepressant effect.
• This effect was observed after both single and repeated (5-day) oral administration.
• Proproten significantly decreased immobility time in the Porsolt's test and increased wheel turns in the Nomura's test, comparable to amitriptyline.
• Unlike amitriptyline, Proproten did not induce a sedative effect.

Conclusions:

• Proproten demonstrates significant antidepressant properties in preclinical models.
• Its efficacy is comparable to amitriptyline, but it offers an advantage by lacking sedative side effects.
• Proproten represents a promising novel therapeutic agent for depression with a potentially improved safety profile.